Investors File Class Action Lawsuit Against Fractyl Health Over Revita DMR
A federal class action lawsuit now targets Fractyl Health, Inc., alleging the metabolic therapeutics firm misled shareholders about the clinical efficacy of its Revita DMR System. The litigation follows a sharp 68% share price collapse in January 2026 after the company revealed disappointing data from its REMAIN-1 study.
The complaint, filed by the law firm Robbins LLP, centers on the window between January 13, 2025, and January 29, 2026. Investors claim the company concealed significant operational failures at clinical sites and overstated the potential of the Revita procedure, which is designed to treat type 2 diabetes and obesity by modifying duodenal dysfunction. According to the court filings, these undisclosed issues compromised the integrity of the REMAIN-1 Midpoint Cohort's results.
The market reacted violently on January 29, 2026, when Fractyl disclosed that Revita-treated patients experienced a 4.5% weight regain, while simultaneously admitting the cohort lacked sufficient power for efficacy analysis. CEO Harith Rajagopalan attributed the poor performance to site-specific irregularities. The stock plummeted $1.245, shedding over 68% of its value in a single session. A subsequent downgrade by Morgan Stanley pushed shares down an additional 21.7% by the following day.
Robbins LLP is currently seeking a lead plaintiff to represent the class. Investors who incurred losses during the specified period have until October 20, 2026, to file for the position. Participation in the action does not require upfront costs, as the firm operates on a contingency fee basis.
Comments (0)
No comments yet. Be the first!